After obtaining his medical degree at the University of Sherbrooke in 2011, Dr Guillaume Richard-Carpentier completed his residency in internal medicine and hematology at the University of Montréal in 2016. He pursued his training in the Clinician-Investigator Program and the Masters in Biomedical Sciences and Clinical Research at the University of Montréal between 2016 and 2018, supported by the Cole Foundation Clinical Fellow Grant. During his masters, he conducted research on prognostic biomarkers in acute myeloid leukemia as part of the Leucegene group under the direction of Guy Sauvageau and Josée Hébert. Dr Richard-Carpentier then completed a clinical and research fellowship in Leukemia at the University of Texas MD Anderson Cancer Center from 2018 to 2020.
Dr Richard-Carpentier’s primary focus is the care of patients diagnosed with acute leukemias or myelodysplastic syndromes. His research interests include the design and conduct of early phase clinical trials to develop novel personalized therapies for these patients. He is also interested in correlative studies embedded in clinical trials to develop biomarkers to improve risk stratification models and predict response to therapy.